Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy

BACKGROUND: Echocardiograms are recommended every 3 months in patients receiving human epidermal growth factor 2 (HER2)-targeted therapy for surveillance of left ventricular ejection fraction (LVEF). Efforts to tailor treatment for HER2-positive breast cancer have led to greater use of non-anthracyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Anthony F., Dang, Chau T., Jorgensen, Justine, Moskowitz, Chaya S., DeFusco, Patricia, Oligino, Eric, Oeffinger, Kevin C., Liu, Jennifer E., Steingart, Richard M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996968/
https://www.ncbi.nlm.nih.gov/pubmed/36895062
http://dx.doi.org/10.1186/s40959-023-00163-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996968/
https://www.ncbi.nlm.nih.gov/pubmed/36895062
http://dx.doi.org/10.1186/s40959-023-00163-4

Ejemplares similares